Datasets:

ravistech

/

clinical-trial-llm-v2

like 0

Follow

ravistech 6

Study Objectives Video-assisted counseling has been shown to improve consistency of counseling regarding a wide variety of health-care related issues. West Cancer Center has shown a significant increase in breast cancer susceptibility gene testing in ovarian cancer patients following video-assisted counseling compared to traditional provider-led counseling. This trial is designed to determine if video-assisted counseling can improve HPV vaccination rates by providing consistent counseling in a timely fashion. Conditions: Human Papillomavirus Infection Intervention / Treatment: BEHAVIORAL: Counseling

Inclusion Criteria: Males and females ages 9-18 years who have not completed the HPV vaccination series and Parents or legal guardians of children ages 9-18 who have not completed the HPV vaccination series who are enrolled in the study Exclusion Criteria: * Pregnancy* Hypersensitivity to yeast* Hypersensitivity to prior HPV vaccination

Study Objectives The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the study, subjects will receive study drug (CS-7017) or placebo in combination with carboplatin and paclitaxel to evaluate effectiveness and safety. The study will find out if adding CS-7017 to carboplatin and paclitaxel will be safe and improve progression free survival in subjects with metastatic non-small cell lung cancer. Conditions: Metastatic Non-small Cell Lung Cancer Intervention / Treatment: DRUG: CS7017 tablets, DRUG: Paclitaxel, DRUG: Carboplatin, DRUG: Placebo Tablets

Inclusion Criteria: * Histologically or cytologically confirmed metastatic (stage IV) NSCLC with no significant pleural effusion or pleural involvement from the tumor * Age greater than or equal to 18 years * Adequate organ and bone marrow function Exclusion Criteria: * Any prior systemic therapy for NSCLC * Major surgical procedure or other investigational agents within 4 weeks before study enrollment * Need for concomitant use of other thiazolidinediones during the study * History of any of the following conditions within 6 months prior to initiating study treatment: Diabetes mellitus requiring treatment with insulin or sulfonylureas or thiazolidinediones (TZDs) agents; Myocardia infarction with significant impairment of cardia function; Malabsorption syndrome, chronic diarrhea, inflammatory bowel disease or partial bowel obstruction; * Clinically active brain metastases, uncontrolled seizure disorder; spinal cord compression or carcinomatous meningitis